Regan M J, Hellmann D B, Stone J H
Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA.
Rheum Dis Clin North Am. 2001 Nov;27(4):863-86, viii. doi: 10.1016/s0889-857x(05)70240-4.
The two principal aims in the treatment of Wegener's granulomatosis (WG) are to limit the extent and severity of permanent organ damage by controlling the disease promptly and to minimize the short- and long-term morbidity that often results from therapy. Remission is considered to be the absence of disease activity in any organ system. Once the disease has been controlled by the initial treatment regimen, which is dictated by the degree of disease severity, the focus of therapy shifts to maintaining disease remission, often with medications less toxic than those used to induce remission. The description of WG treatments in terms analogous to cancer chemotherapy (i.e., those designed to induce remissions and those intended to maintain them) is useful in the formulation of current disease management strategies and in the investigation of new therapies for WG.
韦格纳肉芽肿(WG)治疗的两个主要目标是通过迅速控制疾病来限制永久性器官损害的范围和严重程度,并尽量减少治疗常常导致的短期和长期发病率。缓解被认为是任何器官系统均无疾病活动。一旦疾病通过由疾病严重程度决定的初始治疗方案得到控制,治疗重点便转向维持疾病缓解,通常使用比诱导缓解所用药物毒性更小的药物。用类似于癌症化疗的术语(即那些旨在诱导缓解和维持缓解的术语)来描述WG治疗,对于制定当前的疾病管理策略以及研究WG的新疗法很有用。